Candel Therapeutics Inc (NASDAQ:CADL) has a beta value of -1.23 and has seen 0.82 million shares traded in the recent trading session. The company, currently valued at $446.09M, closed the recent trade at $10.03 per share which meant it gained $0.51 on the day or 5.36% during that session. The CADL stock price is -45.56% off its 52-week high price of $14.60 and 86.64% above the 52-week low of $1.34.
The consensus among analysts is that Candel Therapeutics Inc (CADL) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.19.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Sporting 5.36% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CADL stock price touched $10.03 or saw a rise of 2.05%. Year-to-date, Candel Therapeutics Inc shares have moved 15.55%, while the 5-day performance has seen it change 20.99%. Over the past 30 days, the shares of Candel Therapeutics Inc (NASDAQ:CADL) have changed 50.49%.
Candel Therapeutics Inc (CADL) estimates and forecasts
The company’s shares have gained 90.32% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -46.75% over the past 5 years. Earnings growth for 2025 is a modest -15.27% while over the next 5 years, the company’s earnings are expected to decrease by -1.01%.
CADL Dividends
Candel Therapeutics Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
The top two institutional holders are NORTHPOND VENTURES, LLC with over 1.94 million shares worth more than $12.0 million. As of 2024-06-30, NORTHPOND VENTURES, LLC held 6.477% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 0.82 million shares as of 2024-06-30. The firm’s total holdings are worth over $5.1 million and represent 2.819% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios – Biotechnology and iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 12.06% shares in the company for having 3.92 shares of worth $40.12 million while later fund manager owns 555.0 shares of worth $5.69 million as of Nov 30, 2024, which makes it owner of about 1.71% of company’s outstanding stock.
